Market Report; 223 Pages
Over the past 30 years, cord blood and cord tissue have gained popularity and commercial traction due to the valuable stem cells they contain. Umbilical cord blood (UCB) contains hematopoietic stem cells (UCB-HSCs) that can be used for a diverse range of medical applications. Similarly, umbilical cord tissue (UCT) contains mesenchymal stem cells (UCT-MSCs) that are being evaluated in hundreds of clinical trials to treat various diseases.
In many cases, banking of cord blood and cord tissue can confer health benefits to either the donor or the donor’s siblings due to partial or exact human leukocyte antigen (HLA) matching. HLA matching can reduce, and in some cases eliminate, serious medical complications such as graft-versus-host disease (GvHD) upon transplantation. Moreover, allogeneic (meaning, donor derived) cord blood units and umbilical cord tissue derived mesenchymal stem cells (UCT-MSC) are immune advantaged, which can allow donor-recipient mismatches at some HLA loci to be well tolerated in transplantations and infusions.
Unfortunately, only about 30% of all recipients can be matched with an HLA-identical donor through worldwide registries.
Another problem with the use of umbilical cord blood (UCB) transplantation for the reconstitution of hematopoiesis is the low yield of hematopoietic progenitor cells present in cord blood. A single unit of cord blood typically provides only enough cells to allow for the treatment of children. To overcome this problem, transplanting physicians may use double UCB transplantations to increase the number of HSCs. However, double UBC transplantation leads to greater acquisition costs.
Therefore, in recent years, the number of transplantations using UCB has been declining. Be The Match Registry in the U.S. started its supply of CBU’s for commercial transplantations in 2001 with 45 treatments. The number reached 1,178 in at its peak and then gradually it declined to 686 transplantations in 2018. This downward trend in utilization is concerning for the industry.
Nonetheless, cord blood, with all its therapeutic properties, is an important source of cells for regenerative medicine applications across a diverse range of diseases.
According to ClinicalTrials.gov, there are approximately 1,300 clinical trials evaluating the use of cord blood stem and progenitor cells. These studies use unmanipulated whole cord blood (total nucleated cells/TNC), mononuclear cells (MNC), or cord blood-derived mesenchymal stem cells (MSCs).
The studies are targeting clinical indications that range from pulmonary diseases to infertility to orthopedic conditions, but the most common area of research is neurologic conditions—such as stroke, cerebral palsy, autism and hypoxic ischemic encephalopathy.
The current trend is that the release of cord blood units (CBU) for preclinical and clinical trial investigation is increasing. When paired with clinical trials evaluating the use of cord tissue-derived cells for regenerative medicine applications, the numbers are even more staggering.
As evidence, in 2006 Cord Blood Registry (the largest cord blood bank in the United States) released only 2 CBUs for regenerative medicine and 33 units for hematopoietic stem cell transplantation. By 2019, CBR released 488 units for use in regenerative medicine and 100 units for transplantation.
This shift toward the use of cord blood and tissue within regenerative medicine applications is stunning. The cord blood industry has also been witnessing record levels of M&A activity, with market leaders gaining market share at the expense of niche and specialty competitors and large investment groups vying for acquisition opportunities.
Novel pricing strategies, product cross-sells and upsells, and ingenious online and offline marketing strategies are being implemented by the industry’s market leaders. Meanwhile, new technologies to support ex vivo cord blood expansion are advancing at brisk speed.
If you are competing within the global cord blood banking market, then you know it is becoming increasingly competitive and the rate of change is exponential.
Given the rapidly developing and competitive nature of this global market, you don’t have the time to do the research. Claim this market report to become immediately informed, without sacrificing hours of unnecessary research.
Recently released, this 232-page global strategic report will position you to:
- Capitalize on emerging trends
- Improve internal decision-making
- Reduce company risk
- Approach outside partners and investors
- Outcompete your competitors
- Implement an informed and advantageous business strategy in 2021
Cord Blood Report Highlights
Among its valuable contributions, this report presents a detailed market size determination, including a market size breakdown by geography, indication, and type of bank. It presents future projections for each market segment through 2027. It reveals the number of cord blood units stored in inventory by the largest cord blood banks worldwide and the number of cord blood units (CBUs) released by registries across the world for HSCT.
It reveals the identities of companies offering cord blood storage, cord blood technologies, and cord blood therapeutics on a global basis. Although cord blood is now used to treat 80 different diseases, this number will expand as regenerative medicine applications begin receive approvals in healthcare markets worldwide.
Overall, the report answers the following questions:
- Number of cord blood units cryopreserved in public and private cord blood banks globally
- Number of hematopoietic stem cell transplants (HSCTs) globally using cord blood cells
- Utilization of cord blood cells in clinical trials for developing regenerative medicines
- The decline of the utilization of cord blood cells in HSC transplantations since 2005
- Emerging technologies to influence financial sustainability of public cord blood banks
- The future scope for companion products from cord blood
- The changing landscape of cord blood cell banking market
- Extension of services by cord blood banks
- Types of cord blood banks
- Economic model of public cord blood banks
- Cost analysis for public cord blood banks
- Economic model of private cord blood banks
- Cost analysis for private cord blood banks
- Profit margins for private cord blood banks
- Pricing for processing and storage in private banks
- Rate per cord blood unit in the U.S. and Europe
- Indications for the use of cord blood-derived HSCs for transplantations
- Diseases targeted by cord blood-derived MSCs in regenerative medicine
- Cord blood processing technologies
- Number of clinical trials, number of published scientific papers and NIH funding for cord blood research
- Transplantation data from different cord blood registries
Key questions answered within the report are:
- What are the strategies being considered for improving the financial stability of public cord blood banks?
- What are the companion products proposed to be developed from cord blood?
- How much is being spent for processing and storing a unit of cord blood?
- How much does a unit of cryopreserved cord blood unit fetch on release?
- Why do most public cord blood banks incur a loss?
- What is the net profit margin for a private cord blood bank?
- What are the prices for processing and storage of cord blood in private cord blood banks?
- What are the rates per cord blood units in the U.S. and Europe?
- What are the revenues from cord blood sales for major cord blood banks?
- Which are the different accreditation systems for cord blood banks?
- What are the comparative merits of the various cord blood processing technologies?
- What is to be done to increase the rate of utilization of cord blood cells in transplantations?
- Which TNC counts are preferred for transplantation?
- What is the number of registered clinical trials using cord blood and cord tissue?
- How many clinical trials are involved in studying the expansion of cord blood cells in the laboratory?
- How many matching and mismatching transplantations using cord blood units are performed on an annual basis?
- What is the share of cord blood cells used for transplantation from 2000 to 2020?
- What is the likelihood of finding a matching allogeneic cord blood unit by ethnicity?
- Which are the top ten countries for donating cord blood?
- What are the diseases targeted by cord blood-derived MSCs in clinical trials?
VIEW TABLE OF CONTENTS:
With an online readership of nearly one million viewers per year, BioInformant is a U.S. market research firm with 15 years of experience. As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Headquartered in Washington, DC, BioInformant is strategically positioned to be near the National Institutes of Health (NIH), the U.S. FDA, the Maryland Biotech Corridor, and policy makers on Capital Hill.
The content within this report was compiled using a diverse range of sources, as described in this Research Methodology.
Remember, all BioInformant products come with a Greater Than 100% Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money, and you can keep the product.
Have questions? Email us at [email protected] to get a rapid reply. Checkout below to get immediate access to this report, with printing rights allowed.